Key Takeaways
- • Benchmark Co. analyst Bruce Jackson reiterated a Buy rating on MiniMed Group (NASDAQ: MMED) with a $20.00 price target, implying 40.25% upside from the $14.26 closing price.
- • MiniMed delivered strong fiscal 2026 results with record revenue of $3.1 billion and Q4 net sales of $837 million, up 15.6% on a reported basis and 8.7% organically.
- • Consensus analyst rating reflects Strong Buy sentiment across the Street, with 11 analysts covering the stock and a consensus price target of $21.20; Wells Fargo also assigned a Buy rating with a $22.00 price target.
- • The analyst reiteration follows MiniMed's product pipeline expansion and growing international demand, positioning the company as a beneficiary of its drug delivery platform strategy.
Summary
Benchmark Co. maintained its constructive stance on MiniMed Group following the company's fourth-quarter and full-year 2026 earnings announcement. Analyst Bruce Jackson reaffirmed a Buy rating with a $20.00 price target, suggesting meaningful upside from recent trading levels. At the time of the rating, MiniMed shares closed at $14.26, representing a 40.25% gap to Benchmark's target valuation.
MiniMed's underlying financial performance supports the bullish thesis. The company reported record fiscal 2026 revenue of $3.1 billion, driven by strong fourth-quarter execution. Q4 net sales reached $837 million, representing growth of 15.6% on a reported basis and 8.7% on an organic basis, demonstrating both top-line expansion and underlying operational momentum. However, the company posted a GAAP net loss of $119 million for the quarter ending January 31, indicating that profitability remains under pressure despite solid revenue growth.
The broader analyst community endorses the positive view on MiniMed's prospects. According to TipRanks data, MiniMed benefits from a Strong Buy consensus rating across 11 analyst firms, with an average price target of $21.20. This consensus reflects alignment among institutional research teams on the company's medium-term value creation potential. Notably, Wells Fargo also issued a Buy rating with a $22.00 price target, reinforcing confidence in the therapeutic and commercial opportunity. Benchmark's Jackson, who covers healthcare sector stocks including companies such as Abbott Laboratories and Humacyte, brings sector-specific expertise to his coverage.
The investment rationale centers on MiniMed's drug delivery pipeline maturation and expanding international market penetration. The reiteration of analyst coverage following quarterly results underscores confidence that the company's product launches and geographic expansion can sustain revenue growth momentum and eventually drive margin expansion as the business scales.
MiniMed's underlying financial performance supports the bullish thesis. The company reported record fiscal 2026 revenue of $3.1 billion, driven by strong fourth-quarter execution. Q4 net sales reached $837 million, representing growth of 15.6% on a reported basis and 8.7% on an organic basis, demonstrating both top-line expansion and underlying operational momentum. However, the company posted a GAAP net loss of $119 million for the quarter ending January 31, indicating that profitability remains under pressure despite solid revenue growth.
The broader analyst community endorses the positive view on MiniMed's prospects. According to TipRanks data, MiniMed benefits from a Strong Buy consensus rating across 11 analyst firms, with an average price target of $21.20. This consensus reflects alignment among institutional research teams on the company's medium-term value creation potential. Notably, Wells Fargo also issued a Buy rating with a $22.00 price target, reinforcing confidence in the therapeutic and commercial opportunity. Benchmark's Jackson, who covers healthcare sector stocks including companies such as Abbott Laboratories and Humacyte, brings sector-specific expertise to his coverage.
The investment rationale centers on MiniMed's drug delivery pipeline maturation and expanding international market penetration. The reiteration of analyst coverage following quarterly results underscores confidence that the company's product launches and geographic expansion can sustain revenue growth momentum and eventually drive margin expansion as the business scales.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.